Article Text

Download PDFPDF

P180 Correlation between patient reported outcomes of health-related quality of life and clinical activity in systemic lupus erythematosus patients
  1. Elena Grau-García1,
  2. Samuel Leal-Rodríguez1,
  3. Cristóbal Pávez-Perales1,
  4. Cristina Alcañiz-Escandell1,
  5. Inés Cánovas-Olmos1,
  6. Inmaculada Chalmeta-Verdejo1,
  7. Marta De-la-Rubia-Navarro1,
  8. Jorge Juan Fragio-Gil1,
  9. Roxana González-Mazarío1,
  10. Luis González-Puig1,
  11. José Ivorra-Cortés1,
  12. Isabel Martínez-Cordellat1,
  13. Carmen Nájera-Herranz1,
  14. Rosa Negueroles-Albuixech1,
  15. José Eloy Oller-Rodríguez1,
  16. Francisco Miguel Ortiz-Sanjuán1,
  17. Elvira Vicens-Bernabeu1,
  18. Daniel Hervás-Marín2 and
  19. José Andrés Román-Ivorra1
  1. 1Rheumatology Dept., Hospital Universitario y Politécnico de La Fe, Valencia
  2. 2Biostatistics Unit. Instituto de Investigación Sanitaria La Fe, Valencia, Spain


Background/Purpose Patient-Reported Outcomes (PROs) allow us to know how the disease could affect patients, and maybe could not be detected by clinical measures. Among these, PROs of health-related quality of life (PRO-QL) represents patient evaluation of its health status. In systemic lupus erythematosus (SLE) patients, the heterogeneous inflammatory symptoms can affect the health-related quality of life in different ways.

We aimed to measure the PRO-QL in SLE patients and correlate them with the clinical activity of the disease.

Methods A cross-sectional observational study with SLE patients diagnosed according to SLICC 2012 criteria was performed. SLEDAI score was carried out, and patients full-filled questionnaires of fatigue (FACIT-FATIGUE), quality of life (EQ-5D-5L), disability (HAQ) and a Global Health Status Scale (GHS) (0–100). Biostatistical analysis was performed using the multivariate analysis of variance by Pillai test.

Results 54 SLE patients (91.84% female) with a mean age at diagnosis of 27.55±13.21 years and a mean time of disease evolution of 20.45±9.7 years were included. Mean SLEDAI score was 6.63±6.89, with a 37.04% of patients with SLEDAI>6. The 64.66% of patients were under glucocorticoid treatment, 38.77% under immunosuppressants (methotrexate, azatioprine or mycophenolate) and 51.02% under antimalarials.

Patients showed a mean score of 34.02±12.38 in FACIT-FATIGUE, 0.72±0.26 in EQ-5D-5L, 0.62±0.71 in HAQ and 64.02±25.93 in GHS.

Statistical analysis showed correlation among high SLEDAI scores and low scores of EQ-5D-5L, FACIT-FATIGUE and GHS, and an increment in HAQ, considering as correcting factors the age, years of disease evolution, glucocorticoid treatment, antimalarials and immunosuppressants (P=0.0107).

Conclusions We observed a correlation between PROs-QL full-filled by SLE patients with the clinical activity of the disease, independently of glucocorticoid treatment, antimalarials and immunosuppressants, the age and the disease evolution.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.